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Abstract 
Introduction: Long-term cessation of oral anticoagulation (OAC) following successful 
catheter or surgical ablation of atrial fibrillation (AF) is debated. Usually, in the presence of 
sinus rhythm at serial ECG recordings, the CHADS2, CHA2DS2VASc, and HAS-BLED 
scores are adopted to guide decision regarding OAC management. 
Areas covered: The safety of OAC cessation in patients without recurrent AF but with 
historically elevated risk for thromboembolism remains largely unknown. Taking the cue 
from two clinical cases, we provide an updated summary of the latest evidence regarding how 
to manage OAC after a successful atrial fibrillation ablation.  
Expert commentary: The present clinical perspective suggests that, at least within patients 
with severely enlarged left atrium, previous cardiac surgery and catheter or surgical AF 
ablation, especially if repeated, assessment of atrial contractility by transthoracic 
echocardiography should be performed before discontinuing OAC in patients who maintain 
sinus rhythm, confirmed by serial ECG or Holter monitorings.  
 
Key words: atrial contractility, atrial fibrillation ablation, ECG, echocardiography, oral 
anticoagulation. 
 
Abbreviation list:  
AF: atrial fibrillation  
CT: computed tomography  
MRI: magnetic resonance imaging 
OAC: oral anticoagulation  
TIA: transient ischemic attack 
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1. Introduction 
Atrial fibrillation (AF) is a leading cause of thromboembolic events including strokes, 
transient ischemic attacks (TIA) [1] and silent cerebral infarctions [2]. AF ablation has 
become an effective strategy for symptomatic drug refractory AF [3,4]; however, indication 
for oral anticoagulation (OAC) to prevent thromboembolic events after a successful procedure 
is still debated.  
This uncertainty is reflected by current guidelines. On the one hand, the 2010 Canadian atrial 
fibrillation guidelines suggested that “in the presence of sustained normal sinus rhythm, OAC 
should be discontinued only if the long-term risk of stroke is low (CHADS2 score <2)” [5]. 
On the other hand, the 2014 American and 2016 European atrial fibrillation guidelines 
provided no specific recommendation on long-term OAC use after successful atrial 
fibrillation ablation [6,7].  
In routine clinical practice the CHADS2, CHA2DS2VASc, and HAS-BLED scores are, in 
fact, adopted to guide decision regarding OAC management [8,9]. 
Nevertheless, AF ablation has proved to reduce the risk for subsequent thromboembolic 
events to the level of patients with no history of AF indifferently of CHADS score and age 
[10]. In addition, several studies supported feasibility and safety of discontinuing OAC after 
successful ablation reporting low thromboembolic and reduced bleeding risks [11-15]. 
 
2. Clinical series 
Given the aforementioned evidences, OAC discontinuation following a successful AF 
ablation may become challenging.  
The first clinical example is based on a 67-year-old man. Since a rheumatic endocarditis 
complicated by peripheral embolization, he was on OAC. In 1984, he underwent mitral valve 
replacement with a biological prosthesis. In 1993 the mitral bio-prosthesis, due to rupture of a 
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cusp, was replaced with a mechanical valve, newly urgently replaced by a bio-prosthesis, in 
2007, because of paravalvular leak. In the meantime, in 2005, due to symptomatic persistent 
AF despite antiarrhythmic drugs, he underwent radiofrequency transcatheter AF ablation 
(pulmonary veins isolation, left atrium roof and mitral lines) and, three months later, because 
of atrio-ventricular blocks, a DDD pace-maker was implanted. 
Eventually the patient was referred to our Department, in March 2013, for progressive 
dyspnea worsening. Echocardiography showed a well-functioning bio-prosthesis but a severe 
aortic regurgitation. In October he therefore underwent aortic and mitral (visualization of 
thrombotic material) valve replacement by bio-prosthesis, AF cryoablation by box lesion of 
the pulmonary veins, mitral isthmus line, and left appendage closure by suture of the ostium 
by 2 layers of polypropylene from inside the left atrium.   
Following surgical intervention, he presented the ECG shown in Figure 1 (Panel A), 
apparently showing no atrial activity. At pace-maker interrogation, however, endocavitary 
markers showed sensed atrial (1.5 mV) and ventricular (15.6 mV) activity. Furthermore, atrial 
activity could be captured (0.75V@0.5ms), although not visible on the ECG, demonstrated by 
1:1 atrioventricular conduction at the paced rate (Figure 1, Panel B). At transthoracic 
echocardiography the left atrium was severely dilated (max/min area 35,4 cm2/29 cm2; 
max/min volume 159 ml/119 ml). At transmitral Doppler the A wave was not present and at 
both lateral and septal tissue Doppler scans the a’ wave was poorly perceivable (Figure 2). 
Overall, the total atrial function, including both reservoir and conduct function, was estimated 
around 25%.  
 
The second example is a 68-year-old woman. Since 1999 moderate aortic regurgitation and 
moderate-to-severe mitral regurgitation with preserved left ventricular ejection fraction were 
diagnosed. Due to increasing dyspnea with palpitations, in January 2012, she referred to our 
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Department with rapid ventricular response (150 bpm) AF; on that occasion, besides other 
drugs, OAC was started. A month later an electric cardioversion was performed restoring 
sinus rhythm but symptomatic AF relapse promptly occurred. At echocardiography aortic 
regurgitation had progressed towards moderate-to-severe and severe mitral regurgitation was 
associated with a giant left atrium (area 40 cm2, volume 167 ml). A surgical intervention was 
therefore performed to replace the aortic valve with a biologic prosthesis, to repair the mitral 
valve and to ablate AF by cryoablation (pulmonary veins box, mitral isthmus line and a line 
towards the left appendage). After surgical intervention, the patient recovered well and 
presented the ECG showed in Figure 3; however, due to persistence of symptomatic AF 
paroxysms, in November 2012, an electrophysiologic mapping was performed and the 
reconnected right superior pulmonary vein isolated (Figure 4, Panel A). At transthoracic 
echocardiography the severely enlarged left atrium displayed a scarcely apparent a’ wave on 
tissue Doppler (Figure 4, Panel B and C), highlighting the absence of mechanical contractility 
irrespective of the presence of a clearly evident P wave on ECG. 
 
3. Discussion 
The presented cases are outmost and any physician would recommend oral anticoagulation 
therapy based on clinical wisdom. It is known that AF ablation achieves better results in 
patients with normal or mildly enlarged left atrium [16], however  it is not contraindicated 
also in patients with severely enlarged atrial volumes and decreased atrial contractility. The 
present clinical perspective points out how the ECG-guided approach, on which AF ablation 
success/failure is traditionally based, may be unreliable, suggesting that the assessment of the 
atrial anatomy and mechanical function by transthoracic echocardiography may add 
significant data for the decision process of continuing/discontinuing OAC after “successful” 
AF ablation. 
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Nowadays many efforts are directed towards identifying simple prognostic parameters for the 
prediction of clinical outcomes after AF ablation. Within several attempts P-wave duration 
and morphology at surface ECG, reflecting the process of electrical and structural 
remodelling, have been suggested. Caldwell J et al. [17] showed that the presence of pre-
existent prolonged P-wave duration (>140 ms) is associated with a higher risk of paroxysmal 
AF recurrence post ablation; whereas Park JK et al. [18] demonstrated that basal P-wave 
amplitude in lead I <0.1 mV is an independent predictor of clinical recurrence of AF after 
ablation. On the other side, Kizilirmak F et al. [19] reported that patients with greater 
reduction in P wave amplitude on post-procedural ECG have lower recurrence rates. None of 
these esperiences, however, focused on the relation to subsequent thromboembolic risk. In our 
work, we suggest the hypothesis that after AF ablation the reduced P wave amplitude on ECG 
may correspond to a static LA and therefore to a higher risk of thromboembolism (as in the 
first clinical case); on the other hand, also when a clearly evident P wave is detectable on 
ECG after AF ablation, the LA contractility may not be adequate to prevent the formation of 
thrombi in a severely enlarged LA (as in the second clinical case). Thus, in addition to ECG 
analysis we suggest a direct evaluation of the structural LA remodelling by transthoracic 
echocardiography to better stratify the risk of systemic thromboembolism.  
Other potential parameters have been suggested to predict the risk of systemic 
thromboembolism after AF ablation. For example Proietti M et al. [20] showed a high 
prevalence of abnormal carotid intima-media thickness in AF patients, particularly in case of 
the persistent/permanent form of the arrhythmia and carotid/vertebral atherosclerosis is per se 
associated with an increased risk of ischemic events (Paciaroni M et al [21]). In addition, 
TLAA isolation t needs to be taken into account: Fassini G et al. [22] affirmed, although in 
patients with non-valvular AF, that combined transcatheter AF ablation and LAA closure by 
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percutaneous devices in patients high risk of stroke or contraindication to antithrombotic 
treatment, appears feasible and related to no clinical thromboembolic events in the follow-up.  
Indeed AF ablation patients have reported significantly lower risk of stroke compared to AF 
patients who do not undergo ablation [23] and this lower risk spans across all age groups [24] 
and all CHADS risk profiles [10]. In addition, reports have suggested that cessation of OAC 
after successful AF catheter ablation may result in a very low incidence of thromboembolic 
complications and in a reduced bleeding risk. Themistoclakis et al. [12] published the pooled 
outcomes of 3355 patients who were AF-free following ablation. OAC was discontinued in 
2692 (80.2%) patients after 3-6 months. The thromboembolic risk for patients in whom OAC 
was discontinued amounted to 0.03%/year, similar to that of 0.23%/year for those patients on-
OAC. The major bleeding rate was, instead, 0.98%/year for patients on-OAC versus 
0.02%/year for those in whom it was discontinued (P <0.0001). No embolic events were 
recorded in moderate-high risk patients (CHADS ≥2) off-OAC. Indeed these patients 
represented only a minority (13%, n=347) of the entire cohort. Nevertheless, the Authors 
conclude that, also stratified by CHADS score, the risk-benefit ratio favoured OAC 
discontinuation even in patients with a moderate-high TE risk (CHADS scores 1 and ≥2). 
Saad et al. [13] examined the long-term risk of thromboembolic events off-OAC in 327 
patients with a successful AF catheter ablation. OAC was discontinued in 91% of the patients 
(switched to antiaggregants), none of whom had a thromboembolic event during follow-up. 
Three (0.9%) hemorrhagic strokes were, instead, reported in patients receiving OAC. 
Eventually, Winkle et al. [14] evaluated 108 patients with a prior thromboembolic stroke/TIA 
who underwent successful AF ablation. OAC was discontinued in 55 (50.9%) after a mean 
period of 7.3 months following the successful ablation procedure. No thromboembolic event 
occurred in the off-OAC group.  
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Also after surgically managed atrial fibrillation ablation the number of thromboembolic 
events is low and appears unrelated to the CHADS2 [25], indicating that the decision to 
discontinue OAC after the Cox-Maze procedure should not be based solely on CHADS2 
scores; rather, rhythm status, echocardiographic findings, and patient risk for bleeding should 
be considered [26].  
Although surely representative, the aforementioned experiences report residual 
thromboembolic risk in off-OAC patients and relevant bleeding risk in on-OAC patients 
suggesting clear need for improvement.  
As a consequence, despite AF ablation success defined on sinus rhythm restoration at ECG 
and maintenance by serial 24h Holter recordings, additional data, especially on atrial 
contractility, may be needed.  
Buber et al. [27] showed that a lack of LA mechanical contraction in sinus rhythm patients at 
three months after surgery was associated with a 5-fold increase in the risk for stroke during 
follow-up. Larger atria imposed a significant risk as well; LA volume index ≥33 ml/m2 was 
associated with a 3-fold risk increase. 
The origin of thrombi is predominantly from the left appendage, although the atrium is, 
especially this cohort of patients, a known source. The reduction in contractility occurs in the 
whole left atrium, then thrombus formation more likely will occur in anatomical sites more 
prone to blood stasis, as the left appendage. The assessment of left atrial contractility by 
means of transthoracic echocardiography therefore permits to infer the overall risk of 
thrombus formation in any atrial site. A more precise evaluation of the presence/absence of 
thrombi in the left appendage should needs instead be performed by transesophageal 
echocardiography.  
Rossillo et al. [11] suggested atrial contractility assessment at transesophageal 
echocardiography amongst the criteria for continuing/discontinuing OAC following 
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successful AF ablation. A transesophageal echocardiographic evaluation was performed in all 
patients at 3-month follow-up examination. On TEE, the presence of a higher peak velocity 
and a prolonged duration of early and end diastolic left appendage flow emerged as markers 
of improved contractility. In fact, no cardiovascular accidents, despite OAC discontinuing, 
occurred in patients with maintained atrial contractility at a follow-up of 15±7 months. 
Eventually, also left atrial appendage (LAA) morphology may play a role in predicting 
thromboembolic risk. Even after controlling for comorbidities and CHADS score, patients 
presenting a linear, non-complex LAA morphology (e.g. Chicken Wing) at cardiac CT or 
MRI have shown to be less prone to embolic events [28]. Furthermore, LAA morphology 
complexity related to the burden of silent cerebral ischemia detected at cerebral MRI [29].  
 
4. Limitations 
The present perspective is just a point of departure, suggesting a new approach or 
“sensibility” in clinical practice. The presented clinical cases represent a minimal portion of 
the real world but, in our opinion, relevantly sustain the importance of the topic at least within 
patients undergoing AF ablation and valve surgery. In any case we are convinced  the concept 
introduced by the present manuscript may have application in a wider framework. 
 
5. Conclusion 
The present clinical perspective suggests that, at least within patients with severely enlarged 
left atrium, previous cardiac surgery and catheter or surgical AF ablation, especially if 
repeated, assessment of atrial contractility by transthoracic echocardiography should be 
performed before discontinuing OAC also in patients who maintained sinus rhythm, 
confirmed by serial ECG or Holter monitorings. Further studies are warranted to investigate if 
this evaluation may be needed in all patients undergoing AF ablation and which 
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echocardiographic parameters, including perhaps morphological markers, may be most 
representative with the aim to further improve management of AF patients. 
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6. Expert commentary 
Even if arrhythmia abolition represents the most important goal of AF ablation procedure, the 
preservation of postoperative atrial contractility proved to be an important point for stroke 
risk evaluation. It is reasonable to think that the absence of an efficacious mechanical atrial 
action recovery even if associated with sinus rhythm detection could favour intra-atrial 
thrombi formation and consequent thromboembolic systemic phenomena, thus making the 
decision to interrupt anticoagulant treatment unsafe. 
In our opinion sinus rhythm and left atrial contractility recovery represent two inseparable 
arms of the same question, and both should be weighed up carefully with the objective of 
screening patients who could fully benefit from OAC continuation/discontinuation after AF 
ablation. 
 
7. Five-year view 
The population in the Western world is growing older and in 5 years atrial fibrillation will 
continue the trend towards increased prevalence.  
Also the success of ablative strategies will continue to enhance with the progress of 
technological advances [30,31]. 
There is a need for improvement in patient stratification and personalization of care after 
atrial fibrillation ablation. 
One area that could be further developed is stroke risk stratification, where our understanding 
of which patients should continue anticoagulants for stroke prevention could be further 
refined. A better understanding of that risk may make it possible to reduce in future the 
number of patients receiving anticoagulation after a successful AF ablation, lowering in this 
way the number of hemorrhagic complications. On the other hand, it will endorse the 
continuation of OAC in patients with a higher risk profile, preventing thromboembolic events. 
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In this context, the echocardiographic assessment of the restoration of an efficient left atrial 
contractility will probably be included amongst the criteria for continuing/discontinuing OAC 
following successful AF ablation. 
 
8. Key issues 
• Atrial fibrillation (AF) ablation has become an effective strategy for symptomatic drug 
refractory AF. 
• Indication for oral anticoagulation (OAC) to prevent thromboembolic events after a 
successful procedure is still debated. 
• In routine clinical practice the CHADS2, CHA2DS2VASc, and HAS-BLED scores are 
adopted to guide decision regarding OAC management. 
• Nevertheless, AF ablation has proved to reduce the risk for subsequent 
thromboembolic events to the level of patients with no history of AF indifferently of 
CHADS score and age.  
• In addition, several studies supported feasibility and safety of discontinuing OAC after 
successful ablation reporting low thromboembolic and reduced bleeding risks. 
• The assessment of atrial anatomy and mechanical function by transthoracic 
echocardiography may add significant data for the decision process of 
continuing/discontinuing OAC, in patients who maintain sinus rhythm, confirmed by 
serial ECG or Holter monitorings, after a successful AF ablation. 
• A lack of left atrial mechanical contraction in sinus rhythm patients is associated with 
an increase in the risk for stroke during follow-up. Larger atria impose a significant 
risk as well. 
• Our perspective is just a point of departure, suggesting a new “sensibility” in clinical 
practice. The presented clinical cases represent a minimal portion of the real world but, 
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in our opinion, relevantly sustain the importance of the topic at least within patients 
undergoing AF ablation and valve surgery.Further studies are warranted to investigate 
if this evaluation may be needed in all patients undergoing AF ablation and which 
echocardiographic parameters, including perhaps morphological markers, may be 
most representative with the aim to further improve management of AF patients.  
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Figure Legends 
Figure 1. ECG of the first clinical example. Panel A: ECG of the first clinical example 
following the last surgical intervention, apparently showing no atrial activity; central box: 
pace-maker report with endocavitary markers showing sensed atrial and ventricular activity 
(not having the possibility to describe the axis on the ECG, the hypothesis that the sensed p 
wave could be due to retrograde conduction of a junctional rhythm cannot be excluded). 
Panel B: ECG during atrial pacing (as confirmed by pace-maker report in the central box) 
demonstrating, although no visible atrial activity on the ECG, a 1:1 atrioventricular 
conduction at the paced rate.  
Figure 2. Echocardiographic evaluation of atrial contractility in the first clinical case (A: 
maximum area and maximum volume by Simpson’s method in two-dimensional apical four-
chamber view; B: minimal area and minimal volume by Simpson’s method in two-
dimensional apical four-chamber view; C: pulsed-wave Doppler of transmitral flow showing 
no A wave; D: Doppler tissue image of lateral mitral annulus demonstrating a poorly 
perceivable a’ wave). 
Figure 3.  ECG of the second clinical example following the last surgical intervention, 
showing a clearly evident P wave. 
Figure 4. Left atrium voltage-map and echocardiographic assessment of the second 
clinical example. Panel A: Posterior and lateral views of the left atrium voltage-map of the 
second clinical case showing low voltages (below 0.04 mV) on the entire posterior wall (due 
to previous cryosurgical ablation) and presence, instead, of higher voltages at the ostium of 
the right superior pulmonary vein resulted reconnected (target for subsequent isolation); 
Panel B: area and volume of the left atrium by Simpson’s method in two-dimensional apical 
four-chamber view; Panel C: Doppler tissue image of lateral mitral annulus demonstrating a 
poorly apparent a’ wave.  
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Figure 4 
 
 
 
 
 
 
 
 
 
